Although these chemotherapy agents provide convenience and ease, they are subject to hepatic first-pass metabolism and enzymatic drug-drug interactions.
Jeffrey Fudin, BS, PharmD, DAIPM, FCCP, FASHP, FFSMB
Advertisement
Articles by Jeffrey Fudin, BS, PharmD, DAIPM, FCCP, FASHP, FFSMB
Advertisement
Latest Updated Articles
Be Mindful of DDIs Between Analgesics and Oral Cancer DrugsPublished: April 26th 2019 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Blenrep for Treatment of Relapsed or Refractory Multiple Myeloma
2
Two Doses of PCV20 in Lymphoma Survivors Elicits Greater Humoral Response
3
Early Real-World Experience with VIMKUNYA Consistent with Clinical Trial Findings
4
Elinzanetant Demonstrates Rapid and Sustained Efficacy in Reducing Vasomotor Symptoms Across OASIS Clinical Trials
5
